Class dossier · MILITARY · Draft
Soviet Military & State-Sponsored Pharmacology
The Soviet pharmacology programmes that have no Western analogue are the ones the West did not see. Radioprotectors for nuclear-industry workers. Antidotes for chemical-warfare agents. Blood substitutes for submarines. Adaptogens for spetsnaz in Afghanistan. Each programme was developed inside a closed institute under a closed mandate; the residue that surfaced into the open literature is what survives here. Six institutions dominate the work. The S.M. Kirov Military Medical Academy in Leningrad (now St. Petersburg), where the actoprotector programme was born. The Volgograd Centre for Biologically-Active-Substance Safety, where the adamantane actoprotectors were scaled. The Burnazyan Institute of Biophysics under FMBA, where the radioprotector thread ran through Vasin, Ushakov and Ilyin. The Institute of Theoretical and Experimental Biophysics at Pushchino, where Perftoran — the world's first approved perfluorocarbon blood substitute — was developed by Maevsky and Ivanitsky in the 1980s. The Institute of Toxicology in St. Petersburg, where Petrov, Sofronov and Nechiporenko produced the modern Russian oxime and carbamate antidote line. And GosNIIOKhT — Vol'sk-17, the closed-city nerve-agent institute where Mirzayanov worked on the A-series before he defected and disclosed the programme to Moscow News in 1992. The compounds came out of programmes that were never declassified in full. The clinical-validation populations were never the ones a Western RCT would draw from — they were cosmonauts (IMBP), submarine crews (GNIIiVM), spetsnaz (VMA, FMBA), nuclear-industry workers at Mayak, Chelyabinsk-40, Seversk and Zheleznogorsk, and the Chernobyl liquidators. That is why the dossier includes a 'Voynich' axis as a first-class organising principle: a substantial fraction of what was developed is closed-formula, closed-protocol, and reconstructable only from the residue in the open Russian-language literature.
1 · Definition
- Definition
- Soviet military and state-sponsored pharmacology — compounds developed under the closed programmes of the USSR Ministry of Defence, the Academy of Medical Sciences, the Ministry of Atomic Energy (Минатом), and the cosmonaut programme (IMBP). Includes (1) RADIOPROTECTORS for nuclear-industry and submarine crews; (2) ANTIDOTES (chelating agents for arsenic/heavy-metal, oxime reactivators for organophosphates); (3) PERFTORAN-class oxygen carriers for submarine patrols and field surgery; (4) ADAPTOGENS as a doctrinal class (Lazarev 1958 SNPS) descended into Brekhman-Dymov phytoadaptogen research; (5) the closed end-user programmes (cosmonaut, submarine, spetsnaz) where all of these were validated. Does NOT include actoprotectors (separate dossier) or peptide bioregulators (separate dossier), although the lineages cross at the Kirov Military Medical Academy.
- Criteria
- Developed under a closed programme of USSR MoD, Минатом, Academy of Medical Sciences, or IMBP; End-user validated in military / cosmonaut / nuclear-industry / submarine populations (per CyberLeninka publication or dissertation); Published in Russian-language primary literature (CyberLeninka / disserCat / patents) with at least one cited primary URL; Has a 'Voynich flag' on the basis of how much of the development history is publicly reconstructable
- Origin note
- The category is functional (end-user programme), not chemical. The five scaffold-classes covered here — aminothiol / mercaptobenzimidazole radioprotectors, dimercaprol chelators, oxime AChE reactivators, perfluorocarbon emulsions, phytoadaptogens — are separate scaffolds that converged under one operational doctrine: keep the operator functional in extreme environments.
2 · Provenance
- Institution
- Multiple — see institution roster
- Organizations
- S.M. Kirov Military Medical Academy (Военно-медицинская академия им. С.М. Кирова, ВМА), Leningrad/St. Petersburg — actoprotector programme (Morozov IS lineage), FOV antidotes (carboxime, aminostigmine, pentiphine), military toxicology curriculum · All-Russian Centre for Biologically-Active-Substance Safety (ВНЦ БАВ, Volgograd) — Morozov IS, Sergeeva SA, Krasnykh LM, Safronenko AV; adamantane actoprotector branch of the VMA programme · Burnazyan State Scientific Centre of the Russian Federation — Institute of Biophysics (ГНЦ РФ — Институт биофизики, FMBA, Moscow) — Vasin MV / Ilyin LA / Ushakov IB radioprotector thread; closed-city indralin programme · Zakusov Research Institute of Pharmacology (НИИ фармакологии РАМН / НМИЦ им. В.В. Закусова, Moscow) — bemitil pre-clinical / clinical; Mashkovsky MD's galantamine / adamantane work · Institute of Theoretical and Experimental Biophysics (ИТЭБ РАН, Pushchino) — Maevsky EI / Ivanitsky GR — Perftoran · Institute of Toxicology of the Ministry of Health (Институт токсикологии Минздрава, St. Petersburg) — Petrov AN / Sofronov GA / Nechiporenko SP — OP-antidote pharmacology (carboxime, aminostigmine, pentiphine) · Institute of Medical-Biological Problems RAS (ИМБП РАН, Moscow) — cosmonaut pharmacology (Phenotropil/Suvorov NN; perftoran validation; biosatellite pharmacology) · Institute of Biochemical Physics RAS (ИБХФ РАН, Moscow) — Iasnetsov VV hydroxypyridine actoprotectors · Russian State Medical University (РСМУ, Moscow) — silicon-containing heterocycles programme · Far Eastern Branch of the USSR Academy of Sciences (Дальневосточный филиал АН СССР) — Brekhman II / Dymov IV — pantocrine / eleutherococcus phytoadaptogens · Scientific-Research Institute-2 (НИИ-2 МО РФ) / Research Institute of Military Medicine, MoD RF — military toxicology; antidote pre-clinical (carboxime); organophosphate defence · State Scientific-Research Institute for Military Medicine Testing (ГНИИИВМ) — submarine, aviation, cosmonaut pharmacology programme · Institute of Organic Chemistry, Nat. Acad. Sci. Ukraine (Винница) — Ademol (the only non-Russian actoprotector — Ukrainian SSR origin)
- Key people
- Morozov IS (Морозов И.С.) — VMA → Volgograd, founder of the adamantane actoprotector line, lead author RU 1646256 (1991) bromantane/chlodantane patent; Sergeeva SA (Сергеева С.А.) — ВНЦ БАВ Volgograd, bromantane pharmacokinetics; Krasnykh LM (Красных Л.М.) — ВНЦ БАВ Volgograd, 1995 doctoral dissertation on adamantane-actoprotector PK; Vasin MV (Васин М.В.) — Burnazyan / FMBA, canonical Russian radioprotector researcher (indralin / B-190 thread, dog-to-human extrapolation paper 2022); Ushakov IB (Ушаков И.Б.) — FMBA / IMBP, radioprotector and cosmonaut pharmacology; Ilyin LA (Ильин Л.А.) — Минатом-era radioprotector researcher; Maevsky EI (Маевский Е.И.) — ITEB Pushchino, lead Perftoran pharmacologist; Ivanitsky GR (Иваницкий Г.Р.) — ITEB Pushchino biophysics director, Perftoran co-originator; Petrov AN (Петров А.Н.) — Institute of Toxicology St. Petersburg, lead author of the canonical 2004 Russian FOV-antidote review; Sofronov GA (Софронов Г.А.) — Institute of Toxicology, carbamate / aminostigmine / pentiphine line; Nechiporenko SP (Нечипоренко С.П.) — FMBA, FOV therapy review co-author; Lazarev NV (Лазарев Н.В., 1908–1994) — Leningrad, founder of the СНПС / adaptogen doctrine 1958; Brekhman II (Брехман И.И.) — Far East pharmacology, canonical pantocrine / eleutherococcus paper PMID 5788767 (1969); Dymov IV / Dardymov IV (Дымов И.В. / Дардымов И.В.) — Far East, pantocrine / eleutherococcus; Petrunkin VE (Петрункин В.Е.) — VMA, Unithiol inventor (late 1950s); Suvorov NN (Суворов Н.Н.) — IMBP, Phenotropil (fonturacetam) lead chemist; Mirzayanov VS (Мирзаянов В.С.) — GosNIIOKhT, A-series / Foliant defector-whistleblower (1992 disclosure)
- Intellectual lineage
- Multiple, by sub-programme. RADIOPROTECTORS: Bacq ZM / Alexander P (UK aminothiol chemistry 1940s-50s) → USSR closed programme (Минатом + AMS) → Vasin MV + Ushakov IB + Ilyin LA (Burnazyan/FMBA) — Vasin 2022 dog-to-human extrapolation paper is the most recent canonical Russian publication. ANTIDOTES: Peters / Stocken / Thompson (Oxford 1940s BAL) → USSR Petrun'kin VE (Unithiol, VMA 1950s, water-soluble) → Aposhian HV (US 1980s-90s DMPS clinical development) → Petrov AN + Sofronov GA + Nechiporenko SP (Institute of Toxicology, carboxime / aminostigmine / pentiphine, late 1990s-2000s). ADAPTOGENS: Lazarev NV (Leningrad 1958 СНПС doctrine) → Brekhman II + Dymov IV (Far East, pantocrine / eleutherococcus) → Barnaulov OD + Osipova TV (St. Petersburg, 2012 stress-limiting review). PERFTORAN: Japanese Fluosol-DA + US Green Cross (1970s) → Maevsky EI + Ivanitsky GR (ITEB Pushchino, late 1970s-early 1980s) → Russian registration 1996 (world's first PFC blood-substitute approval)..
- COI note
- Structural COI throughout — the discovery principal is in nearly every case also the principal validator / commercial beneficiary. The Vasin indralin thread is the cleanest (a single researcher's career-long publication record, no commercial ties), but indralin is pre-clinical/registration-only — not commercialised. Perftoran is a registered drug (Maevsky+Ivanitsky), but the early-1980s submarine clinical files are not in the public record. The Voynich axis (closed compounds, classified dosing protocols, multi-drug auto-injector combinations) is the structural feature that distinguishes this dossier — not the COI per se. Honest framing: the state that produced these compounds does not want you to see the whole programme; the residue in the open Russian literature is what survives.
3 · Mechanism — claim by claim
01
Radioprotectors act by SH-group free-radical scavenging (aminothiol class: cystamine, indralin) — protect against ionising radiation damage to bone marrow and gut epithelium; the Soviet programme deployed them as pre-exposure prophylaxis for nuclear-submarine crews, strategic-rocket crews, nuclear-industry workers (Mayak, Chelyabinsk-40, Seversk, Zheleznogorsk), Chernobyl liquidators, and civil-defence first-aid kits. Vasin 2022 (DOI 10.33266/1024-6177-2022-67-3-5-12) showed indralin radioprotection extrapolates from dogs to humans at meaningful dose ratios — the closest thing to a clinical-trial proxy.
Two-generation programme: cystamine (1950s, USSR Academy of Medical Sciences) → indralin / B-190 (1970s, Vasin thread at Burnazyan/FMBA). Indralin replaced cystamine in the Russian first-aid kit post-Chernobyl. 2024-2026 comparative studies in Bull Exp Biol Med (PMIDs 28239785, 38730104, 39126544) place indralin against riboxin, copper chlorophyllin, trolox, and glutathione/ascorbate combinations.
02
Chelating antidotes (Unithiol / DMPS / DMSA / BAL) work by binding arsenic, mercury, lead through dithiol chemistry, forming stable water-soluble complexes that are renally excreted. Petrun'kin VE's late-1950s Unithiol (DMPS-Na, the Soviet water-soluble answer to British BAL) is the canonical Soviet development. The Western clinical development of Unithiol = DMPS (sodium 2,3-dimercapto-1-propane sulfonate), developed by Aposhian HV (Univ. of Arizona) in the 1980s-90s and confirmed in PMID 9703487, PMID 1563599, PMID 24178900. Multipolar lineage: a Soviet invention developed into a Western clinical standard.
Petrun'kin's 1950s paper is open (PMID 4468608 on Unithiol for arsenic). The DMPS development is well-documented. The 100-year Russian toxicology review (Sarmanayev / Simonenko 2021, CyberLeninka) covers the full lineage.
03
Oxime AChE reactivators (Pralidoxime, Obidoxime, Dipyroxime/TMB-4, Isonitrosine, HI-6, Carb-oxime) work by nucleophilic attack on the P-O bond at the AChE esteratic site, restoring enzymatic function after organophosphate inhibition. The Soviet doctrine favoured bis-pyridinium dioximes (dipyroxime/TMB-4 was the principal Soviet nerve-agent reactivator from the 1960s until ~1991). After the breakup of the USSR, Latvian TMB-4 production ceased, forcing the Institute of Toxicology to develop carb-oxime (carbamate-oxime, partial BBB penetration, stable ≥3 yr at ≤25 °C) as the Russian successor.
Carb-oxime + aminostigmine (prophylactic carbamate) + pentiphine (M1+nicotinic blocker) = the modern Russian triple-drug defence. Petrov 2004 (Ros. khim. zh. 48(2):110-116) is the canonical review. Gladdkikh / Nazarov 2014 reviews cholinesterase reactivators in the экстремальная биомедицина context.
04
Adaptogens (Lazarev doctrine 1958: СНПС — state of non-specifically increased resistance) act by raising non-specific resistance to stressors without targeting any single pathway. Brekhman-Dymov 1969 (PMID 5788767, Lloydia) is the canonical English-language paper establishing ginseng + eleutherococcus + pantocrine as members of the same phytoadaptogen class. The Soviet military pharmacy included all three for fatigue recovery in paratroopers, submariners, and sustained-operation troops.
The doctrine is open; the military-implementation specifics (which adaptogens were selected for which troops, at which doses, in which combinations) are partially classified. Barnaulov / Osipova 2012 reviews the stress-limiting properties of classical phytoadaptogens. Studenzov / Ramsh / Kazurova 2013 '50 years of searching' situates the modern descendants.
05
Perftoran (perfluorodecalin + perfluoro-N-(4-methylcyclohexyl)-piperidine emulsion, 10% w/v with Proxanol-268 surfactant) carries dissolved O2 in plasma independently of haemoglobin, enabling oxygenation in the absence of donor blood. Designed specifically for closed-environment Soviet nuclear-submarine crews (where blood transfusion is impossible on patrol). Registered in Russia 1996 — the world's first perfluorocarbon blood-substitute approval. Never FDA-approved in US; ECMO-vs-Perftoran comparative review (Khadartsev / Kireev / Ivanov 2020) is the modern open thread.
The Maevsky/Ivanitsky 1980s ITEB Pushchino work is well-published. The closed 1980s submarine-clinical-programme validation data are not in the public record. Sofronov/Boyko/Kulikov 2012 covers safe-route study. Modern comparative review with hemocyanin/perfluorocarbon in Chinese Journal of Applied Physiology (PMID 40925714, 2025).
4 · Roster — verified compounds
| Name | Subclass | Institution / status | Year | Note | Voynich |
|---|---|---|---|---|---|
| Cystamine | Radioprotector (aminothiol) | USSR AMS + Минатом | 1950s | Russian first-aid kit (AI-2 successor) | LOW |
| Indralin (B-190) | Radioprotector (mercaptobenzimidazole) | Burnazyan / FMBA — Vasin MV | 1970s | Russian first-aid kit post-Chernobyl | partial — pre-clinical dossier open, human clinical files not |
| Indometophen (BTH-Ph) | Non-steroidal estrogenic radioprotector | USSR closed programme — Tarumov RA, Myasnikov VA | 1980s | Pre-clinical only | high — single Russian paper, development history largely absent |
| Unithiol (DMPS-Na) | Dithiol chelating antidote | VMA кафедра фармакологии — Petrun'kin VE | late 1950s | Russian first-aid kit АИ-2 + successors; civilian heavy-metal poisoning treatment | low — original paper open, Western DMPS development well published |
| Carboxime | Bis-quaternary mono-oxime AChE reactivator | Institute of Toxicology, St. Petersburg — Petrov AN / Sofronov GA | late 1990s-2000s | Russian military first-aid kit (replaces dipyroxime/TMB-4) | partial — published monotherapy open, auto-injector multi-drug combination not |
| Aminostigmine | Carbamate reversible AChE inhibitor (prophylactic) | Institute of Toxicology, St. Petersburg — Sofronov / Prozorovskii | 1991-1992 | Approved in Russia for central anticholinergic syndrome; studied as FOV prophylactic | LOW |
| Pentiphine | M1 + nicotinic cholinoblocker | Institute of Toxicology — Kosmachev/Belyaev/Sofronov | 1998-2003 | Component of modern Russian multi-drug kit (П-10М) | LOW |
| Pantocrine | Phytoadaptogen (Siberian maral antler extract) | Far Eastern Branch USSR AS + NIIFARM — Brekhman II + Dymov IV | 1930s (folk); 1960s formal pharmacology | Veterinary use + Russian OTC tonic | low — Brekhman-Dymov 1969 PMID 5788767 canonical |
| Eleutherococcus | Phytoadaptogen (Siberian ginseng) | Far Eastern Branch USSR AS — Brekhman + Dardymov | 1960s onwards | Russian OTC tonic; military pharmacy | LOW |
| Ginseng (Panax) | Classical phytoadaptogen (ginsenosides) | Leningrad / Far East — Lazarev school + Brekhman | 1940s onwards | Worldwide; Soviet military pharmacy | LOW |
| Perftoran | Perfluorocarbon O2 carrier emulsion | ITEB Pushchino — Maevsky EI + Ivanitsky GR | late 1970s-early 1980s | Registered Russia 1996 (world's first PFC blood-substitute); used in trauma / surgery | partial — Maevsky publications open; 1980s submarine clinical files not |
5 · Voynich index — partially-declassified compounds
The 'Voynich' analogy is deliberate: like the Voynich manuscript, Soviet military pharmacology is a large body of work that exists in fragmented form across Russian-language primary literature, with no consolidated public dossier and no civilian regulatory trail. The state that produced it does not want you to see the whole.
High Voynich (closed protocol / pre-clinical only)
- B-190 / indralin — pre-clinical dossier in Vasin publication thread is open, but human clinical files are not
- Carboxime — published as monotherapy; the military auto-injector multi-drug combination is not
- Ethomersol — pre-clinical only; referenced in Morozov-lineage papers but no clinical file
- Thiazoloindoles (12 compounds) — VMA programme, 5 of 12 active in exhaustive-load tests; 4 active in acute hypercapnic hypoxia; pre-clinical only
- 3-Hydroxypyridines (IBKhF-1 / -11 / -14) — out-perform bemitil and bromantane in treadmill/swim tests; pre-clinical only; the Iasnetsov 2011 paper is the single open publication
- 1-Oxa-4-aza-2-silacyclanes — RSMU silicon chemistry; mixed signals; pre-clinical only; 8 compounds studied
- Indometophen — non-steroidal estrogenic radioprotector; single Russian-language paper; development history largely absent
- Perftoran — military / submarine dosing protocols are open (Maevsky's published papers), but the closed-programme validation data from the 1980s are not
Low Voynich (open literature, civilian registration)
- Bemitil — extensively civilian-registered
- Bromantane — civilian-registered as Ladasten; PK/PD data in published papers
- Unithiol — original Petrun'kin 1950s paper is open; DMPS is the Western clinical development, well published
- Pantocrine / Eleutherococcus / Ginseng — extensively published; Brekhman-Dymov 1969 is the canonical English-language paper (PMID 5788767)
- Cystamine — first-aid-kit radioprotector; standard pharmacology open
6 · End-user programmes — closed clinical populations
| Programme | Institution | Compounds validated | Voynich |
|---|---|---|---|
| Cosmonaut pharmacology (IMBP) | ГНЦ РФ — Институт медико-биологических проблем РАН, Moscow | Phenotropil (fonturacetam); bemitil; bromantane; pantocrine; eleutherococcus; perftoran | partial — ISS mission pharmacology published; closed Buran / Almaz / military cosmonaut programmes not |
| Submarine pharmacology (GNIIiVM + 3rd Central Navy Hospital) | ГНИИИВМ (State Research Institute for Military Medicine Testing) | perftoran (submarine patrol O2 carrier); bemitil; bromantane; cystamine; indralin (reactor-starts) | partial — published rescue / safety literature open; closed submarine-crew dosing protocols not |
| Spetsnaz pharmacology (VMA + FMBA) | ВМА + ФМБА | bemitil (Afghanistan 1979-1989); bromantane; pantocrine + eleutherococcus (Afghanistan / Chechnya); carboxime auto-injector; indralin (Chornobyl) | partial — spetsnaz drug combinations published only in oblique form |
| Nuclear-industry pharmacology (Минатом + FMBA) | Минатом + ФМБА; Mayak / Chelyabinsk-40 / Seversk / Zheleznogorsk | cystamine (1950s-onwards); indralin (1970s-onwards, post-Chernobyl replacement) | low — radioprotector programmes extensively published (Vasin / Ushakov / Ilyin thread) |
7 · Multipolar co-development — Soviet-bloc collaboration
| Country | Compounds | Institutions |
|---|---|---|
| Ukrainian SSR | Ademol (actoprotector, Vinnitsa 1990s); Bogomolets anti-reticular cytotoxic serum (Kyiv 1938) | Institute of Organic Chemistry NAS Ukraine (Vinnitsa); Bogomolets Institute (Kyiv) |
| Latvian SSR | Dipyroxime / TMB-4 (oxime AChE reactivator, principal Soviet nerve-agent reactivator 1960s-1991) | Latvian SSR pharmaceutical production (ceased after USSR breakup, forcing carboxime development) |
| Bulgaria | Nivalin (galantamine drug development, Paskov 1956-1959); Pharmachim production of Nivalin | Pharmachim, Sofia |
| Kazakhstan | Pancragen (KEDW tetrapeptide, co-investigated by Tarnovskaya SI / Benberin VV at Almaty Institute of Gerontology) | Institute of Gerontology, Almaty |
8 · Anchors
| Identifier | Claim |
|---|---|
| PMID 5788767 | Brekhman-Dymov 1969 — canonical English-language paper on pantocrine / ginseng / eleutherococcus pharmacology; the foundational citation for the Lazarev adaptogen doctrine's phytoadaptogen descendants |
| PMID 28239785 | 2017 Bull Exp Biol Med — Pharmacological Analysis of cystamine + indralin as radiomitigators |
| PMID 38730104 | 2024 Bull Exp Biol Med — Radioprotective Properties of Riboxin (Inosine) and Indralin under External Irradiation |
| PMID 39126544 | 2024 Bull Exp Biol Med — Comparative Evaluation of Radioprotective Properties of Copper Chlorophyllin, Trolox, and Indralin |
| DOI 10.33266/1024-6177-2022-67-3-5-12 | Vasin / Ilyin / Ushakov 2022 — The Phenomenon of Radiation Protection of Large Animals (Dogs) with Indralin and its Extrapolation to Humans; the closest thing to a clinical-trial proxy for the indralin programme |
| DOI 10.1093/jrr/rru046 | Vasin 2014 — Protective effect and therapeutic index of indralin in juvenile rhesus monkeys |
| PMID 4468608 | Petrun'kin 1976 — Unithiol and mecaptid as antidotes in arsenic-containing substance poisoning; canonical Soviet chelator paper |
| PMID 9703487 | Aposhian 1998 Environ Health Perspect — Mobilization of mercury and arsenic in humans by DMPS; confirms DMPS = Western clinical development of Soviet Unithiol |
| PMID 1563599 | Aposhian 1992 FASEB J — Urinary mercury after DMPS administration |
| PMID 24178900 | Kosnett 2014 J Med Toxicol — The role of chelation in the treatment of arsenic and mercury poisoning |
| PMID 3600025 | Ge / Pu 1987 J Tradit Chin Med — Effects of ginsenosides and pantocrine on reproductive endocrine system in male rats |
| PMID 40925714 | 2025 Chinese Journal of Applied Physiology — hemocyanin/perfluorocarbon review; the modern comparative thread for Perftoran |
| PMID 11271197 | 2001 — cold perfusion of rat livers (transplant preservation; adjacent PFC application) |
| Patent RU 1646256 (1991) | Morozov IS — 2-(para-brombenzoyl) or 2-(para-chlorbenzoyl) aminoadamantanes, повышающие резистентность организма к действию экстремальных факторов среды обитания и обладающие иммуностимулирующей активностью; patent text explicitly names 'авиационно-космической, военной, морской и т.п.' (aerospace, military, marine) as intended use; discontinued 14.07.2005 for non-payment of maintenance fees (BI 16/2006); local mirror at /esperdeck/soviet/bibliography/patents/RU1646256_morozov_1991_bromantane_chlodantane.html |
| CyberLeninka: r/adap-rodstv | Studenzov / Ramsh / Kazurova 2013 — Adaptogens and related groups of drugs: 50 years of searching; situates the Lazarev doctrine and its descendants |
| CyberLeninka: uchenie-n-v-lazareva | Yaremenko 2005 — Lazarev's SNPS doctrine and adaptogens as the base theory of preventive medicine; canonical post-Soviet doctrinal review |
| CyberLeninka: antidoty-fos | Petrov AN / Sofronov GA / Nechiporenko SP / Somin IN 2004 Ros. khim. zh. — Antidotes of organophosphorus poisonous substances; canonical Russian FOV-antidote review |
| CyberLeninka: izuchenie-effektivnosti-r-estradiola | Myasnikov VA / Tarumov RA 2012 Вестник новых медицинских технологий — primary Russian-language paper on indometophen as radioprotector |
| CyberLeninka: vozmozhnosti-ekstrakorporalnoy-membrannoy-oksigenatsii | Khadartsev / Kireev / Ivanov 2020 — ECMO-vs-Perftoran comparative review (modern open thread) |
| CyberLeninka: fenotropil-zakonomernoe-liderstvo | Fedotova 2004 Remedium — Phenotropil profile 'born in the depths of GNTs RF — IMBP RAS'; IMBP-cosmonaut origin |
| disserCat: farmakokinetika-aktoprotektorov | Krasnykh LM 1995 — Pharmacokinetics of adamantane-derivative actoprotectors (Volgograd ВНЦ БАВ) |
9 · Corroboration
- Verified
- 2026-08-27
- Method
- Every Russian-language URL verified live against CyberLeninka. PubMed PMIDs cross-verified via E-utilities. Patents checked against FIPS and Google Patents.
10 · Open questions
- Map the Submarine-crew dosing protocols for Perftoran in the 1980s — what fraction of the published Maevsky papers corresponds to submarine clinical validation vs civilian post-registration use?
- Quantify the indralin dog-to-human extrapolation (Vasin 2022) against the closed Минатом human-protocol files — Vasin is the closest proxy but the actual human data are not in the open literature
- Map the VMA pharmacopoeia: how many of the 196 Khavinson patents list Morozov IS as co-inventor? The 1991 US Patent 5,070,076 is one; the full ledger is the patent-archive answer
- Identify the five thiazoloindoles (Gavreev 2010) and three IBKhF hydroxypyridines (Iasnetsov 2011) that out-perform bemitil/bromantane — these are the next-generation Russian actoprotectors, but the structure-activity data are pre-clinical only
- Cross-reference the Brekhman-Dymov 1969 pantocrine / eleutherococcus corpus with the Far Eastern Branch USSR AS archive holdings — Brekhman's published corpus is canonical; the unpublished lab notebooks are the Voynich residue
- Map the carboxime + aminostigmine + pentiphine multi-drug auto-injector (П-10М / пеликсим) — published only as monotherapy in Petrov 2004; the multi-drug combination is the closed protocol
- Quantify multipolar co-development: Bulgaria (Nivalin/galantamine), Latvia (TMB-4), Ukraine (Ademol), Kazakhstan (Pancragen) — the Soviet bloc was never a single-instrument state
- Cross-reference the IMBP cosmonaut pharmacology programme with the Buran / Almaz / Soyuz-Altair closed military-cosmonaut programme — the published ISS thread is open; the military thread is not